This article examines key innovations driving scalable, high-yield purification of recombinant AAVs and how they’re helping ...
There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector system will be used, with AAV and lentivirus being two of the most commonly ...
Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to enable in vivo gene delivery, today announced that Roche (SIX: RO, ...
SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis ...
Otsuka Pharma enters licensing agreement with 4D Molecular Therapeutics for ophthalmic gene therapy drug candidate, 4D-150: Tokyo Monday, November 3, 2025, 11:00 Hrs [IST] Otsuka ...
DMD gene therapy faces challenges in safety, efficacy, and long-term outcomes, despite FDA approval of delandistrogene moxeparvovec. Future strategies focus on novel AAV capsids, dual/triple vector ...
Four patients with infantile-onset Pompe’s disease received a single intravenous injection of an adeno-associated virus serotype 9 vector carrying codon-optimized complementary DNA encoding human acid ...
OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback